Side effects of systemic oncological therapies in dermatology;Nebenwirkungen onkologischer Systemtherapien in der Dermatologie

JDDG - Journal of the German Society of Dermatology

Volumn 10, Issue 7, 2012, Pages 475-486

  Zimmer, Lisa ^a   Vaubel, Julia ^a   Livingstone, Elisabeth ^a   Schadendorf, Dirk ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

BRAF inhibitor; chemotherapy; ipilimumab; MEK inhibitor; side effects; targeted therapy

Indexed keywords

DABRAFENIB; DACARBAZINE; ETORICOXIB; IPILIMUMAB; LOPERAMIDE; SELUMETINIB; SORAFENIB; TRAMETINIB; VEMURAFENIB;

ADRENAL INSUFFICIENCY; ALOPECIA; ANEMIA; APOPTOSIS; ARTHRALGIA; BLURRED VISION; CANCER THERAPY; CENTRAL SEROUS RETINOPATHY; COLITIS; CONJUNCTIVITIS; DERMATOLOGIST; DERMATOLOGY; DIARRHEA; EOSINOPHILIA; ERYTHEMA; FATIGUE; GENE MUTATION; GLAUCOMA; GLOMERULONEPHRITIS; HAND FOOT SYNDROME; HUMAN; HYPERKERATOSIS; HYPOPHYSITIS; HYPOPITUITARISM; HYPOTHYROIDISM; INTRAOCULAR PRESSURE; IRITIS; KERATOACANTHOMA; LIVER TOXICITY; MENINGITIS; METASTATIC MELANOMA; NAUSEA; NEUROPATHY; NONHUMAN; OUTPATIENT; PANCREATITIS; PAPULAR RASH; PATIENT CARE; PERICARDITIS; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOSENSITIVITY; PNEUMONIA; PRURITUS; RASH; RETINA DETACHMENT; RETINA MACULA EDEMA; RETINA VEIN OCCLUSION; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SQAMOUS CELL CARCINOMA; SQUAMOUS CELL CARCINOMA; UVEITIS; VITILIGO; VOMITING;

ANTINEOPLASTIC AGENTS; DRUG ERUPTIONS; HUMANS;

EID: 84863441045     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/j.1610-0387.2012.07942.x     Document Type: Review

References (54)

1. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA,. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-16.
2. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Hersey P, Kefford R, Lawrence D, Puzanov I, Lewis KD, Amaravadi RK, Chmielowski B, Lawrence HJ, Shyr Y, Ye F, Li J, Nolop KB, Lee RJ, Joe AK, Ribas A,. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012; 366: 707-14.
3. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbe C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ,. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. N Engl J Med 2010; 363: 711-23.
4. Robert C, Thomas L, Bondarenko I, O'Day S, M DJ, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH, Jr., Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD,. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517-26.
5. Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, Gore M, Aamdal S, Cebon J, Coates A, Dreno B, Henz M, Schadendorf D, Kapp A, Weiss J, Fraass U, Statkevich P, Muller M, Thatcher N,. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000; 18: 158-66. (Pubitemid 30036349)
6. Ribas A, Flaherty KT,. BRAF targeted therapy changes the treatment paradigm in melanoma. Nat Rev Clin Oncol 2011; 8: 426-33.
7. Bos JL., ras oncogenes in human cancer: a review. Cancer Res 1989; 49: 4682-9. (Pubitemid 19213607)
8. Zimmer L, Livingstone E, Hillen U, Domkes S, Becker A, Schadendorf D,. Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management. Arch Dermatol 2012; 148 (3): 357-61.
9. Dummer R, Rinderknecht J, Goldinger SM,. Ultraviolet A and photosensitivity during vemurafenib therapy. N Engl J Med 2012; 366: 480-1.
10. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB,. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363: 809-19.
11. Kefford R, Arkenau H, Brown MP, Millward M, Infante JR, Long GV, Oullet D, Curtis M, Lebowitz PF, Falchook GS,. Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. J Clin Oncol 2010; 28: suppl; abstr 8503.
12. Su F, Viros A, Milagre C, Trunzer K, Bollag G, Spleiss O, Reis-Filho JS, Kong X, Koya RC, Flaherty KT, Chapman PB, Kim MJ, Hayward R, Martin M, Yang H, Wang Q, Hilton H, Hang JS, Noe J, Lambros M, Geyer F, Dhomen N, Niculescu-Duvaz I, Zambon A, Niculescu-Duvaz D, Preece N, Robert L, Otte NJ, Mok S, Kee D, Ma Y, Zhang C, Habets G, Burton EA, Wong B, Nguyen H, Kockx M, Andries L, Lestini B, Nolop KB, Lee RJ, Joe AK, Troy JL, Gonzalez R, Hutson TE, Puzanov I, Chmielowski B, Springer CJ, McArthur GA, Sosman JA, Lo RS, Ribas A, Marais R,. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 2012; 366: 207-15.
13. Oberholzer PA, Kee D, Dziunycz P, Sucker A, Kamsukom N, Jones R, Roden C, Chalk CJ, Ardlie K, Palescandolo E, Piris A, MacConaill LE, Robert C, Hofbauer GF, McArthur GA, Schadendorf D, Garraway LA,. RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol 2012; 30: 316-21.
14. Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, Ludlam MJ, Stokoe D, Gloor SL, Vigers G, Morales T, Aliagas I, Liu B, Sideris S, Hoeflich KP, Jaiswal BS, Seshagiri S, Koeppen H, Belvin M, Friedman LS, Malek S,. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010; 464: 431-5.
15. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N,. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010; 464: 427-30.
16. Infante J, Falchook G, Lawrence D, Weber J, Kefford R, Bendell J, Kurzrock R, Shapiro G, Kudchadkar R, Long G, Burris H, Kim K, Clements A, Sun P, Yi B, Allred A, Oullet D, Patel K, Lebowitz P, Flaherty K,. Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436). J Clin Oncol 2011; 29: abstr 8503.
17. Robert C, Arnault JP, Mateus C,. RAF inhibition and induction of cutaneous squamous cell carcinoma. Curr Opin Oncol 2011; 23: 177-82.
18. Dalle S, Poulalhon N, Thomas L,. Vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 365: 1448-9; author reply 50.
19. Zimmer L, Hillen U, Livingstone E, Lacouture ME, Busam K, Carvajal RD, Egberts F, Hauschild A, Kashani-Sabet M, Goldinger SM, Dummer R, Long GV, McArthur G, Scherag A, Sucker A, Schadendorf D,. Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. J Clin Oncol 2012; in press.
20. Falchook G, Infante JR, Fecher LA, Gordon MS, Vogelzang NJ, DeMarini DJ, et al,. The oral MEK1/2 inhibitor GSK1120212 demonstrates early efficacy signals. Paper presented at European Society of Medical Oncology. Milan, 2010.
21. Adjei AA, Cohen RB, Franklin W, Morris C, Wilson D, Molina JR, Hanson LJ, Gore L, Chow L, Leong S, Maloney L, Gordon G, Simmons H, Marlow A, Litwiler K, Brown S, Poch G, Kane K, Haney J, Eckhardt SG,. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol 2008; 26: 2139-46.
22. Balagula Y, Barth Huston K, Busam KJ, Lacouture ME, Chapman PB, Myskowski PL,. Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886). Invest New Drugs 2011; 29: 1114-21.
23. Schad K, Baumann Conzett K, Zipser MC, Enderlin V, Kamarashev J, French LE, Dummer R,. Mitogen-activated protein/extracellular signal-regulated kinase kinase inhibition results in biphasic alteration of epidermal homeostasis with keratinocytic apoptosis and pigmentation disorders. Clin Cancer Res 2010; 16: 1058-64.
24. Robert C, Soria JC, Spatz A, Le Cesne A, Malka D, Pautier P, Wechsler J, Lhomme C, Escudier B, Boige V, Armand JP, Le Chevalier T,. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005; 6: 491-500. (Pubitemid 40903630)
25. Lacouture ME, Anadkat MJ, Bensadoun RJ, Bryce J, Chan A, Epstein JB, Eaby-Sandy B, Murphy BA,. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer 2011; 19: 1079-95.
26. Livingstone E, Trarbach T, Zimmer L, Schuler M, Schadendorf D,. [Interdisciplinary management of cutaneous adverse events of EGFR inhibitors and multityrosine kinase inhibitors in oncology]. Dtsch Med Wochenschr 2011; 136: 39-44.
27. Greenwald RJ, Freeman GJ, Sharpe AH,. The B7 family revisited. Annu Rev Immunol 2005; 23: 515-48. (Pubitemid 40563179)
28. O'Day SJ, Hamid O, Urba WJ,. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer 2007; 110: 2614-27. (Pubitemid 350250330)
29. Hanaizi Z, van Zwieten-Boot B, Calvo G, Lopez AS, van Dartel M, Camarero J, Abadie E, Pignatti F,. The European Medicines Agency review of ipilimumab (Yervoy) for the treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy: summary of the scientific assessment of the Committee for Medicinal Products for Human Use. Eur J Cancer 2012; 48: 237-42.
30. Kahler KC, Hauschild A,. Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanoma. J Dtsch Dermatol Ges 2011; 9: 277-86.
31. Kahler KC, Mustroph D, Hauschild A,. Current recommendations for prevention and therapy of extravasation reactions in dermato-oncology. J Dtsch Dermatol Ges 2009; 7: 21-8.
32. Treudler R, Georgieva J, Geilen CC, Orfanos CE,. Dacarbazine but not temozolomide induces phototoxic dermatitis in patients with malignant melanoma. J Am Acad Dermatol 2004; 50: 783-5. (Pubitemid 38580562)
33. Ulrich J, Hartmann JT, Dorr W, Ugurel S,. Skin toxicity of anti-cancer therapy. J Dtsch Dermatol Ges 2008; 6: 959-77.
34. Levy A, Guitera P, Kerob D, Ollivaud L, Archimbaud A, Dubertret L, Basset-Seguin N,. [Hypersensitivity to dacarbazine in patients with metastatic malignant melanoma]. Ann Dermatol Venereol 2006; 133: 157-60. (Pubitemid 44123849)
35. Kennedy RD, McAleer JJ,. Radiation recall dermatitis in a patient treated with dacarbazine. Clin Oncol (R Coll Radiol) 2001; 13: 470-2. (Pubitemid 34071950)
36. Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SG, Donehower RC,. Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 1993; 20: 1-15. (Pubitemid 23239390)
37. Pazdur R, Kudelka AP, Kavanagh JJ, Cohen PR, Raber MN,. The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere). Cancer Treat Rev 1993; 19: 351-86. (Pubitemid 23333409)
38. Bokemeyer C, Lampe C, Heneka M, Schabet M, Bamberg M, Kanz L,. Paclitaxel-induced radiation recall dermatitis. Ann Oncol 1996; 7: 755-6.
39. Payne JY, Holmes F, Cohen PR, Gagel R, Buzdar A, Dhingra K,. Paclitaxel: severe mucocutaneous toxicity in a patient with hyperbilirubinemia. South Med J 1996; 89: 542-5. (Pubitemid 126590570)
40. Link CJ, Jr., Sarosy GA, Kohn EC, Christian MC, Davis P, Adamo DO, Reed E,. Cutaneous manifestations of Taxol therapy. Invest New Drugs 1995; 13: 261-3.
41. Yamamoto Y, Kawano I, Iwase H,. Nab-paclitaxel for the treatment of breast cancer: efficacy, safety, and approval. Onco Targets Ther 2011; 4: 123-36.
42. Hersh EM, O'Day SJ, Ribas A, Samlowski WE, Gordon MS, Shechter DE, Clawson AA, Gonzalez R,. A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma. Cancer 2010; 116: 155-63.
43. Kottschade LA, Suman VJ, Amatruda T, 3rd, McWilliams RR, Mattar BI, Nikcevich DA, Behrens R, Fitch TR, Jaslowski AJ, Markovic SN,. A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group Study, N057E(1). Cancer 2011; 117: 1704-10.
44. Heidary N, Naik H, Burgin S,. Chemotherapeutic agents and the skin: An update. J Am Acad Dermatol 2008; 58: 545-70. (Pubitemid 351375051)
45. Meyer L, Zuberbier T, Worm M, Oettle H, Riess H,. Hypersensitivity reactions to oxaliplatin: cross-reactivity to carboplatin and the introduction of a desensitization schedule. J Clin Oncol 2002; 20: 1146-7. (Pubitemid 34141861)
46. Markman M, Kennedy A, Webster K, Elson P, Peterson G, Kulp B, Belinson J,. Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol 1999; 17: 1141.
47. Lorusso D, Di Stefano A, Carone V, Fagotti A, Pisconti S, Scambia G,. Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome). Ann Oncol 2007; 18: 1159-64. (Pubitemid 47244360)
48. Krown SE, Northfelt DW, Osoba D, Stewart JS,. Use of liposomal anthracyclines in Kaposi's sarcoma. Semin Oncol 2004; 31: 36-52. (Pubitemid 40023241)
49. Degen A, Alter M, Schenck F, Satzger I, Volker B, Kapp A, Gutzmer R,. The hand-foot-syndrome associated with medical tumor therapy-classification and management. J Dtsch Dermatol Ges 2010; 8: 652-61.
50. Mangili G, Petrone M, Gentile C, De Marzi P, Vigano R, Rabaiotti E,. Prevention strategies in palmar-plantar erythrodysesthesia onset: the role of regional cooling. Gynecol Oncol 2008; 108: 332-5.
51. von Moos R, Thuerlimann BJ, Aapro M, Rayson D, Harrold K, Sehouli J, Scotte F, Lorusso D, Dummer R, Lacouture ME, Lademann J, Hauschild A,. Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts. Eur J Cancer 2008; 44: 781-90.
52. Vail DM, Chun R, Thamm DH, Garrett LD, Cooley AJ, Obradovich JE,. Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: a randomized, double-blind clinical trial using a canine model. Clin Cancer Res 1998; 4: 1567-71. (Pubitemid 28265245)
53. von Gruenigen V, Frasure H, Fusco N, DeBernardo R, Eldermire E, Eaton S, Waggoner S,. A double-blind, randomized trial of pyridoxine versus placebo for the prevention of pegylated liposomal doxorubicin-related hand-foot syndrome in gynecologic oncology patients. Cancer 2010; 116: 4735-43.
54. Basch E, Prestrud AA, Hesketh PJ, Kris MG, Feyer PC, Somerfield MR, Chesney M, Clark-Snow RA, Flaherty AM, Freundlich B, Morrow G, Rao KV, Schwartz RN, Lyman GH,. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2011; 29: 4189-98.